Redcare Pharmacy (Shop Apoth) stock (NL0012044747): shares trade around EUR 43 as investors focus on valuation after steep year-to-date drop

Redcare Pharmacy (Shop Apoth) shares on Xetra hover near EUR 43 after a sharp year-to-date decline, leaving investors to reassess the online pharmacy’s valuation and margin prospects in the Netherlands and Germany ahead of upcoming half-year results.

Redcare Pharmacy (Shop Apoth) shares were recently quoted at around 43.12 EUR on Xetra, leaving the Netherlands-based online pharmacy down more than 30 percent year-to-date as investors in its home market reassess growth and profitability prospects after a period of strong expansion, according to finanzen.net as of 05/29/2026.Finanzen.net as of 05/29/2026 The stock, which is listed in Germany and operates under Dutch regulation, sits well below its 52-week high, reflecting concerns about tighter competition, margin pressure, and the regulatory trajectory in core markets such as Germany and the Netherlands.Finanzen.net as of 05/29/2026

In home-country terms, Redcare Pharmacy trades on Xetra in Frankfurt with the ticker RDC and in euros as trading currency, anchoring the stock firmly in the German equity universe despite the company’s Dutch registration, while its business focus remains on European online pharmacy and mail-order drug sales.Euronext as of 05/29/2026 The share price around 43 EUR implies a substantial pullback from a 52-week peak near 123 EUR, according to German market data, underscoring how sentiment has cooled after a period when digital health and e-prescription themes had driven a much richer valuation multiple.Finanzen.net as of 05/29/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy
• Sector/industry: Online pharmacy and e-commerce healthcare retail
• Headquarters/country: Sevenum, Netherlands
• Core markets: Germany, Netherlands, Belgium and selected European Union countries
• Key revenue drivers: Online prescription and over-the-counter drug sales, non-prescription health products, and marketplace offerings in continental Europe
• Home exchange/listing venue: Xetra (RDC) and Euronext Amsterdam (RDC)
• Trading currency: EUR

Redcare Pharmacy (Shop Apoth): core business model

Redcare Pharmacy runs a pan-European online platform for prescription and over-the-counter medicines, with revenue primarily generated from digital pharmacy orders and health-related e-commerce in Germany and neighboring markets.

Valuation metrics and multiples for Redcare Pharmacy (Shop Apoth)

The pronounced share-price retreat over the last 12 months has had a direct impact on Redcare Pharmacy’s valuation metrics, with market data providers showing a compression in earnings and sales multiples compared with the peak phase of investor enthusiasm for European online pharmacies.Finanzen.net profile as of 05/29/2026 According to public valuation snapshots, the current market capitalization, derived from the roughly 43 EUR share price on Xetra, implies a more moderate price-to-sales ratio than in prior years when expectations for e-prescription adoption and rapid digitalization in the German healthcare system were higher.Finanzen.net as of 05/29/2026

Available data from financial portals indicate that Redcare Pharmacy is not a classic dividend stock, with the investment narrative instead centered on growth, margin expansion and operating leverage in its logistics and technology platform rather than on cash distributions.MarketScreener as of 05/29/2026 In this context, investors studying the current valuation typically focus on metrics such as enterprise-value-to-sales and, where available, forward-looking EBITDA or earnings multiples, using consensus expectations for upcoming half-year and full-year results to gauge whether the present share price embeds cautious or more optimistic assumptions about the trajectory of order volumes and margins.MarketScreener consensus as of 05/29/2026

Conclusion

With Redcare Pharmacy (Shop Apoth) shares changing hands around 43 EUR on Xetra after a pronounced slide from their 52-week highs, the market in the Netherlands and Germany is clearly recalibrating expectations for growth, margins and regulatory support in the online pharmacy space. The current valuation framework, shaped by lower share levels and a focus on enterprise-value-to-sales and other growth-oriented multiples, underscores how upcoming financial disclosures and any shifts in competitive dynamics or healthcare policy could influence whether investors continue to see the stock as fairly valued at these prices or due for further adjustment.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.